These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36344987)

  • 21. Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia-Preliminary results from a randomized controlled trial.
    Wu V; Lee JM; Vozoris NT; Faughnan ME
    Laryngoscope Investig Otolaryngol; 2021 Jun; 6(3):370-375. PubMed ID: 34195356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.
    Yaniv E; Preis M; Shevro J; Nageris B; Hadar T
    Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of the Nasal Outcome Score for Epistaxis in Hereditary Hemorrhagic Telangiectasia (NOSE HHT).
    Peterson AM; Kallogjeri D; Spitznagel E; Chakinala MM; Schneider JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):999-1005. PubMed ID: 33022056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-Related Quality of Life Outcome Measures in Individuals With Hereditary Hemorrhagic Telangiectasia: A Scoping Review.
    Gong AJ; Garg T; Khalil A; Gowda PC; Mathai SC; Rowan NR; Merlo CA; Weiss CR
    Am J Rhinol Allergy; 2024 Jan; 38(1):60-76. PubMed ID: 37855028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
    Iyer VN; Apala DR; Pannu BS; Kotecha A; Brinjikji W; Leise MD; Kamath PS; Misra S; Begna KH; Cartin-Ceba R; DuBrock HM; Krowka MJ; O'Brien EK; Pruthi RK; Schroeder DR; Swanson KL
    Mayo Clin Proc; 2018 Feb; 93(2):155-166. PubMed ID: 29395350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization.
    Khanwalkar AR; Rathor A; Read AK; Paknezhad H; Ma Y; Hwang PH
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):1034-1042. PubMed ID: 34989143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.
    de Jel DVC; Disch FJM; Kroon S; Mager JJ; Verdam FJ
    Angiogenesis; 2020 Aug; 23(3):271-274. PubMed ID: 32112177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal bevacizumab injections improve quality of life in HHT patients.
    Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
    Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
    Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
    Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians.
    Al-Samkari H
    Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.
    Feller CN; Adams JA; Friedland DR; Poetker DM
    Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Septectomy and septal dermoplasty for the treatment of severe transfusion-dependent epistaxis in patients with hereditary hemorrhagic telangiectasia and septal perforation.
    Lesnik GT; Ross DA; Henderson KJ; Joe JK; Leder SB; White RI
    Am J Rhinol; 2007; 21(3):312-5. PubMed ID: 17621815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia].
    Zhang J; Wang XS; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995
    [No Abstract]   [Full Text] [Related]  

  • 38. Sinonasal quality of life outcomes following laser treatment of epistaxis related to hereditary hemorrhagic telangiectasia.
    Kuan EC; Peng KA; Thompson CF; Suh JD; Wang MB
    Lasers Med Sci; 2017 Apr; 32(3):527-531. PubMed ID: 28116537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
    Dupuis-Girod S; Ambrun A; Decullier E; Fargeton AE; Roux A; Bréant V; Colombet B; Rivière S; Cartier C; Lacombe P; Chinet T; Blivet S; Blondel JH; Gilbert-Dussardier B; Dufour X; Michel J; Harle JR; Dessi P; Faure F
    JAMA; 2016 Sep; 316(9):934-42. PubMed ID: 27599328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report.
    Mei-Zahav M; Blau H; Bruckheimer E; Zur E; Goldschmidt N
    J Otolaryngol Head Neck Surg; 2017 Oct; 46(1):58. PubMed ID: 28978360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.